Published in Thyroid on July 01, 2010
The long-term outcomes of the second generation of familial nonmedullary thyroid carcinoma are more aggressive than sporadic cases. Thyroid (2012) 1.08
Familial papillary thyroid carcinoma: a retrospective analysis. J Oncol (2011) 1.04
Risk of Thyroid Cancer in Euthyroid Asymptomatic Patients with Thyroid Nodules with an Emphasis on Family History of Thyroid Cancer. Korean J Radiol (2016) 0.97
Personalized medicine: caught between hope, hype and the real world. Clinics (Sao Paulo) (2012) 0.79
Clinicopathologic characteristics of familial versus sporadic papillary thyroid carcinoma. Acta Otorhinolaryngol Ital (2015) 0.77
Controversies in familial thyroid cancer 2014. Ulus Cerrahi Derg (2014) 0.76
The association between DNA copy number aberrations at chromosome 5q22 and gastric cancer. PLoS One (2014) 0.76
Familial multinodular goiter syndrome with papillary thyroid carcinomas: mutational analysis of the associated genes in 5 cases from 1 Chinese family. BMC Endocr Disord (2013) 0.75
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol (2011) 7.46
Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol (2007) 7.20
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med (2015) 5.07
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med (2012) 4.59
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol (2009) 3.80
Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat Med (2011) 3.60
Collective cell migration requires suppression of actomyosin at cell-cell contacts mediated by DDR1 and the cell polarity regulators Par3 and Par6. Nat Cell Biol (2010) 2.58
Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol (2013) 2.58
Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf) (2014) 2.56
A simple method to cure established tumors by inflammatory killing of normal cells. Nat Biotechnol (2004) 2.39
Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res (2008) 1.91
Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med (2007) 1.74
Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther (2009) 1.72
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res (2012) 1.67
A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2009) 1.60
A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization. Nat Biotechnol (2003) 1.58
Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study. Int J Radiat Oncol Biol Phys (2010) 1.55
Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat Biotechnol (2012) 1.52
Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. Nat Biotechnol (2002) 1.48
Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med (2012) 1.46
A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res (2010) 1.42
Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer Res (2007) 1.37
Thyroid cancer causing obstruction of the great veins in the neck. World J Surg Oncol (2008) 1.35
Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res (2010) 1.35
The biology of the sodium iodide symporter and its potential for targeted gene delivery. Curr Cancer Drug Targets (2010) 1.25
Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J Clin Invest (2010) 1.22
Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther (2012) 1.20
Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clin Cancer Res (2009) 1.17
Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse. Mol Ther (2013) 1.16
Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol Ther (2008) 1.16
Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck. Cancer Res (2007) 1.14
Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas. Cancer Res (2009) 1.09
Disrupting the interaction between HOX and PBX causes necrotic and apoptotic cell death in the renal cancer lines CaKi-2 and 769-P. J Urol (2008) 1.09
Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming. Mol Cancer (2011) 1.04
Targeted radionuclide therapy using a Wnt-targeted replicating adenovirus encoding the Na/I symporter. Clin Cancer Res (2009) 1.04
An exploratory study into the role of dynamic contrast-enhanced magnetic resonance imaging or perfusion computed tomography for detection of intratumoral hypoxia in head-and-neck cancer. Int J Radiat Oncol Biol Phys (2008) 1.00
Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol Ther (2008) 1.00
Early and late toxicity of radioiodine therapy: detection and management. Endocr Pract (2011) 0.99
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. Adv Ther (2013) 0.96
Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide. Mol Ther (2010) 0.95
Bevacizumab-induced hypertension: pathogenesis and management. BioDrugs (2011) 0.95
The value of magnetic resonance imaging in target volume delineation of base of tongue tumours--a study using flexible surface coils. Radiother Oncol (2010) 0.94
Evidence-based review: quality of life following head and neck intensity-modulated radiotherapy. Radiother Oncol (2010) 0.93
Correlation between dose to the pharyngeal constrictors and patient quality of life and late dysphagia following chemo-IMRT for head and neck cancer. Radiother Oncol (2009) 0.93
Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy. Mol Ther (2011) 0.92
Reovirus therapy in cancer: has the orphan virus found a home? Expert Opin Investig Drugs (2008) 0.91
First trimester maternal serum placental protein 13 for the prediction of pre-eclampsia in women with a priori high risk. Prenat Diagn (2009) 0.91
Pulse wave analysis in normal pregnancy: a prospective longitudinal study. PLoS One (2009) 0.91
The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck. Expert Opin Ther Targets (2005) 0.90
Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. Cancer Res (2003) 0.90
Live viruses to treat cancer. J R Soc Med (2013) 0.89
Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders. PLoS One (2008) 0.89
Robotic system for MRI-guided stereotactic neurosurgery. IEEE Trans Biomed Eng (2015) 0.88
Oncolytic viruses: time to compare, contrast, and combine? 5th international meeting on replicating oncolytic virus therapeutics. Banff, Alberta, Canada, 18-22 March 2009. Mol Ther (2009) 0.88
MAPK and PI3K signalling differentially regulate angiogenic and lymphangiogenic cytokine secretion in squamous cell carcinoma of the head and neck. Eur J Cancer (2010) 0.88
Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy. Clin Cancer Res (2006) 0.87
Follicular thyroid carcinoma metastasis to the esophagus detected by 18FDG PET/CT. Thyroid (2008) 0.87
Establishing a large prospective clinical cohort in people with head and neck cancer as a biomedical resource: head and neck 5000. BMC Cancer (2014) 0.87
From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer. Patholog Res Int (2011) 0.86
Virus smuggling, tax evasion and tumor assassination. Nat Med (2006) 0.86
Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer. J Clin Oncol (2009) 0.86
Hyperfractionated Accelerated Radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysis. Int J Radiat Oncol Biol Phys (2009) 0.85
Long-term outcomes following low-dose radioiodide ablation for differentiated thyroid cancer. J Clin Endocrinol Metab (2013) 0.84
Early screening for pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol (2011) 0.84
A Bayesian hierarchical model for DCE-MRI to evaluate treatment response in a phase II study in advanced squamous cell carcinoma of the head and neck. MAGMA (2011) 0.84
Taste preferences for oral nutrition supplements in patients before and after pelvic radiotherapy: a double-blind controlled study. Clin Nutr (2006) 0.83
Enhancing prostate cancer cryotherapy using tumour necrosis factor related apoptosis-inducing ligand (TRAIL) sensitisation in an in vitro cryotherapy model. Cryobiology (2009) 0.83
Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy. Cancer Res (2003) 0.83
Cardiac amyloidosis diagnosed incidentally by bone scintigraphy. J Nucl Cardiol (2007) 0.82
Recent developments and current status of gene therapy using viral vectors in the United Kingdom. BMJ (2004) 0.82
Two-year and lifetime cost-effectiveness of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2013) 0.81
Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines. J Urol (2006) 0.81
Prospective, longitudinal electroglottographic study of voice recovery following accelerated hypofractionated radiotherapy for T1/T2 larynx cancer. Radiother Oncol (2008) 0.81
Bronchial washing levels of vascular endothelial growth factor receptor-2 (VEGFR2) correlate with overall survival in NSCLC patients. Cancer Lett (2011) 0.81
Anemia during sequential induction chemotherapy and chemoradiation for head and neck cancer: the impact of blood transfusion on treatment outcome. Int J Radiat Oncol Biol Phys (2008) 0.80
Adhesion molecules in lung cancer: implications in the pathogenesis and management. Curr Pharm Des (2008) 0.80
Dendritic cells for the immunotherapy of cancer. Clin Oncol (R Coll Radiol) (2002) 0.80
Antihypertensive therapy and central hemodynamics in women with hypertensive disorders in pregnancy. Obstet Gynecol (2009) 0.79
Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia. Biores Open Access (2012) 0.79
Placental production and maternal serum and urine levels of inhibin A and activin A are modified by antihypertensive therapy in hypertensive disorders of pregnancy. Clin Endocrinol (Oxf) (2008) 0.78
Hysteroscopic management of cornual ectopic pregnancy. BJOG (2003) 0.77
The hitchhiker's guide to virotherapy. Oncotarget (2012) 0.77
Talimogene laherparepvec in the treatment of melanoma. Expert Opin Biol Ther (2015) 0.76
Manually after-loaded 192Ir low-dose rate brachytherapy after subtotal excision and flap reconstruction of recurrent cervical lymphadenopathy from head and neck cancer. Radiother Oncol (2006) 0.76
Adjuvant nodal irradiation in melanoma. Lancet Oncol (2012) 0.75
Randomised controlled trials in HBO: "A call to arms" for HOPON & DAHANCA-21. Br J Oral Maxillofac Surg (2009) 0.75
Cable-driven elastic parallel humanoid head with face tracking for Autism Spectrum Disorder interventions. Conf Proc IEEE Eng Med Biol Soc (2010) 0.75
Second trimester maternal serum cystatin C levels in preeclamptic and normotensive pregnancies: A small case-control study. Hypertens Pregnancy (2010) 0.75
Rising thyroglobulin tumour marker during pregnancy in a thyroid cancer patient: no cause for alarm? Clin Endocrinol (Oxf) (2012) 0.75
Electroglottographic analysis of valved speech following total laryngectomy. Logoped Phoniatr Vocol (2008) 0.75